Cargando…
A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer’s disease
INTRODUCTION: Current prescribing guidelines for the antipsychotic amisulpride are based largely on pharmacokinetic (PK) studies in young adults, and there is a relative absence of data on older patients, who are at greatest risk of developing adverse events. METHODS: This study aimed to develop a p...
Autores principales: | Reeves, Suzanne, Bertrand, Julie, D’Antonio, Fabrizia, McLachlan, Emma, Nair, Akshay, Brownings, Stuart, Greaves, Suki, Smith, Alan, Taylor, David, Howard, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989015/ https://www.ncbi.nlm.nih.gov/pubmed/27481049 http://dx.doi.org/10.1007/s00213-016-4379-6 |
Ejemplares similares
-
Misidentification Subtype of Alzheimer's Disease Psychosis Predicts a Faster Cognitive Decline
por: D'Antonio, Fabrizia, et al.
Publicado: (2019) -
Region-specific blood–brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer’s disease
por: Sekhar, Gayathri Nair, et al.
Publicado: (2019) -
Interaction of amisulpride with GLUT1 at the blood-brain barrier. Relevance to Alzheimer’s disease
por: Boyanova, Sevda T., et al.
Publicado: (2023) -
Hyperprolactinaemia with amisulpride
por: Raj, Rajnish, et al.
Publicado: (2008) -
Amisulpride induced mania
por: Aggarwal, Ashish, et al.
Publicado: (2010)